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Abstract 
BACKGROUND: Psoriasis, the prevalence of which ranges from 2% to 3% of the general population, has been 
recently recognised as not only a chronic inflammatory skin disorder but also an immunometabolic systemic 
disease. Dyslipidemia is one of the most important comorbidities of psoriasis. Statins, frequently used as anti-
hyperlipidemic agents, may be beneficial in the treatment of several autoimmune diseases, including psoriasis, 
due to their anti-inflammatory and immunomodulatory characteristics. Hence, we hypothesised that using this 
medication was not only beneficial for reducing hyperlipidemia but also improving psoriatic conditions. 
AIM: We conducted a study to determine the prevalence of dyslipidemia in psoriatic patients as well as whether 
the addition of statins (simvastatin prescribed forms) to standard topical antipsoriatic treatment can improve skin 
lesions in psoriatic patients. 
METHODS: A group of 128 psoriatic patients and 128 healthy controls who were matched with the patients 
regarding ethnicity, age, and sex were enrolled, and their lipid concentrations were determined. Furthermore, sixty 
patients were randomly selected from the former group and divided into two treatment subgroups to evaluate the 
effect of statins on the severity of psoriasis using the PASI score. 
RESULTS: We found that the rate of dyslipidemia in the patient group was significantly higher than in the healthy 
group (53.9% versus 21.9%, p < 0.001), particularly the triglyceride concentration (1.86 ± 1.17 versus 1.43 ± 0.79 
mg/dL, p < 0.001). Also, the PASI score reduction in the simvastatin-treated subgroup was significantly different 
from that in the placebo-treated one after eight weeks of therapy (8.63 ± 4.78 versus 5.34 ± 3.59, p < 0.01). 
CONCLUSION: This study showed that simvastatin might play a role in controlling hyperlipidemia and in turn 
decrease the PASI score in psoriatic patients. 
 
 
 
 
Introduction 
 
Psoriasis is a chronic inflammatory skin 
disease the prevalence of which ranges from 2% to 
3% of the general population, depending on region 
and ethnic origin [1]. Many recent studies support the 
hypothesis that psoriasis results from an interaction 
between an individual’s genetic susceptibility and 
specific environmental factors. Nearly 20 psoriatic-
susceptibility gene loci and genes with a fundamental 
role in psoriasis pathophysiology have been identified, 
including PSORS1 (a major susceptibility gene, 
mapped near the human leucocyte antigen HLACw6) 
[2]. Currently, the various treatment modalities are 
divided into local and systemic treatments, including 
topical steroids, vitamin D3, tar, anthralin, topical 
retinoids, phototherapy, retinoids, methotrexate, 
biologic agents and many other treatment modalities. 
Psoriatic prognosis is unpredictable, and its 
recurrence almost inevitably appears regardless of 
treatment [3]. 
Dyslipidemia is known as one of several 
comorbidities of psoriasis in addition to cardiovascular 
abnormalities, hypertension, atherosclerosis, diabetes 
mellitus type 2, and obesity [4]. Recently, there have 
been several clinical observations focusing on the risk 
of developing cardiovascular diseases, such as acute 
coronary syndromes or arterial hypertension, in 
psoriatic patients. Additionally, other conditions, 
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including hyperlipidemia, obesity and type 2 diabetes, 
were found to be more prevalent in the patient group 
than in the control group [5]. 
Statins, with the most common drugs being 
simvastatin and atorvastatin, form one type of 
compound that can reduce the amount of cholesterol 
in the blood. They were first discovered in 1971 by 
Akira Endo and constitute a rapidly growing class of 
medications that can modulate hypercholesterolemia. 
The beneficial effect of statins on lipids is directly 
linked to the inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme-A reductase, which plays a central role in 
the synthesis of cholesterol in the liver and underlies 
the most beneficial effect of statins on lipids. 
Consequently, statin therapy has been used for the 
prevention of atherosclerosis and cardiovascular 
events [5], [6]. Many studies have shown that statins 
have anti-inflammatory and immunomodulatory 
properties which would be useful in the treatment of 
psoriasis and other cutaneous disorders [7], [8], [9]. 
We conducted a study to determine the 
prevalence of dyslipidemia in psoriatic patients as well 
as whether the addition of statins (simvastatin 
prescribed forms) to standard topical antipsoriatic 
treatment can improve skin lesions in psoriatic 
patients. 
 
 
Patients and methods 
 
Patient population 
This study was conducted from January 2011 
to December 2014 at the Outpatient Department, 
Hospital of Dermato-Venereology, Ho Chi Minh City, 
Vietnam. 
Psoriatic patients, aged more than 18 years 
old, were recruited into the study. The exclusion 
criterion included hypersensitivity to simvastatin or 
calcipotriol/betamethasone dipropionate, renal and 
liver dysfunction, alcohol abuse, muscular disorders, 
use of topical or systemic psoriatic medication in the 
past 1 month, and pregnant and lactating women. 
Two hundred fifty-six patients and healthy 
controls who gave informed consent provided blood 
samples for the evaluation of their lipid profiles. Also, 
sixty patients were randomly selected from the patient 
group and divided into two treatment subgroups. 
Subgroup 1 was treated with oral simvastatin (40 
mg/d divided twice a day) plus topical 
calcipotriol/betamethasone dipropionate ointment for 8 
weeks, and subgroup 2 received only the same topical 
regimen. 
 
 
Efficacy assessment 
A well-trained dermatologist evaluated the 
Psoriasis Area and Severity Index (PASI) score of the 
patients at the baseline, at the 4
th
 week and the 8
th
 
week. Also, the lipid profile was assessed 
simultaneously. Safety was assessed by patients’ 
reports of adverse events, clinical examination, and 
liver function tests. 
 
Statistical analysis 
Data were expressed as the means ± SDs 
and the ratio. Statistical analysis was performed using 
Epi Info™ (Epi Info™ version 3.5.1 for Windows; 
CDC). The data were analysed using Wilcoxon and 
Mann-Whitney tests, the Chi-square test, and two-
tailed Student’s tests. A P value < 0.05 was 
considered statistically significant. 
 
 
 
Results 
 
Baseline characteristics 
The study included 128 patients and 128 
healthy controls. The patients (30 patients in each 
subgroup) were treated for eight weeks. Their 
characteristics are shown in Table 1.  
Table 1: Baseline patient characteristics 
Characterist
ics 
Group 
P value 
Subgroup 
P value Control 
(n = 128) 
Patient 
(n = 128) 
Subgroup 1 
(n = 30) 
Subgroup 2 
(n = 300) 
Gender: 
Men (%) 
Women (%) 
 
64 (50%) 
64 (50%) 
 
64 (50%) 
64 (50%) 
 
1
a 
1
a
 
 
17 (56.7%) 
13 (43.3%) 
 
17 (56.7%) 
13 (43.3%) 
 
1
a 
1
a
 
Mean ± SD. 
age (yr) 
43.3 ± 
12.6 
41.9 ± 
14.7 
0.43
b
 36.0 ± 10.0 39.1 ± 14.5 0.34
b
 
Mean ± SD. 
BMI 
21.9 ± 3.2 
21.9 ± 
3.1 
0.93
b
 - - - 
Mean ± SD. 
Disease 
duration (yr) 
- 7.7 ± 8.1 - 5.8 ± 5.4 5.6 ± 5.4 0.89
b
 
Clinical 
features 
Psoriasis 
vugaris 
Erythroderm
ic psoriasis 
Pustular 
psoriasis 
Arthritis 
psoriasis 
- 
 
100 
(78.1%) 
11 (8.6%) 
 
9 (7%) 
8 (6.3%) 
- 
 
30 (100%) 
0 
 
0 
0 
 
30 (100%) 
0 
 
0 
0 
 
1
a
 
PASI score: 
mean ± SD 
- 
10.9 ± 
7.4 
- 12.8 ± 5.8 11.8 ± 5.1 0.51
b
 
a 
Chi-square test; 
b 
Two–tailed Student’s test. 
 
 
In total, 128 patients (64 male and 64 female) 
and 128 matched controls (64 male and 64 female) 
were included. Patients in subgroup 1 (oral 
simvastatin plus calcipotriol/betamethasone 
dipropionate ointment) consisted of 17 male and 13 
female patients. Subgroup 2 (only 
calcipotriol/betamethasone dipropionate ointment) 
consisted of 17 male and 13 female patients. The 
 Trong et al.. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis. The Vietnamese Experience 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
mean age of the healthy group was 43.3 ± 12.6 years, 
which was correlated with the patient group (41.9 ± 
14.7 years). In subgroup 1, the average age was 36.0 
± 10.0 years, and in subgroup 2, the average age was 
39.1 ± 14.5 years. There was no significant difference 
between sex ratios and mean ages in the two groups. 
 
Figure 1: Comparison of lipid concentration profiles between study 
groups 
 
The mean baseline PASI score in the patient 
group was 10.9 ± 7.4. Specifically, the mean baseline 
PASI score in subgroup 1 was 12.8 ± 5.87, and in 
subgroup 2 it was 11.8 ± 5.1. The difference in the 
mean baseline PASI scores of the two subgroups was 
not statistically significant (P = 0.51). 
 
Dyslipidemia 
The rate of dyslipidemia in the patient group 
was considerably higher than in the healthy control 
group (53.9% versus 21.9%, p < 0.001). The 
percentages of hypercholesterolemia in the psoriasis 
group and control group were 25.0% and 10.9%, 
respectively, (p < 0.01). When we compared the 
frequency of hypertriglyceridemia between the two 
groups, there was a significantly higher frequency in 
the patient group than in the control group (25.0% in 
psoriasis versus 8.6% in controls, p < 0.001). The 
frequency of hypo-HDL-c was significantly different in 
the patients and the controls (21.9% versus 3.9%, p < 
0.001). Each element of the lipid profiles is shown in 
Table 2. 
Table 2: Comparison of the lipid profiles between the study 
groups 
 Group  
P value Patient 
(n = 128) 
Control 
(n = 128) 
Dyslipidemia 69 (53.9%) 28 (21.9%) < 0.001 
Hypercholesterolemia 32 (25.0%) 14 (10.9%) < 0.01 
Hypertriglyceridemia 32 (25.0%) 11 (8.6%) < 0.001 
Hyper-LDL cholesterolemia 19 (14.8%) 12 (9.4%) 0.18 
Hypo-HDL cholesterolemia 28 (21.9%) 5 (3.9%) < 0.001 
Cholesterol/HDL-c > 5 26 (20.3%) 8 (6.3%) < 0.01 
a 
Chi-square test. 
 
Analysing the mean concentration of each 
component in the lipid profiles, our study revealed a 
difference between the triglyceride levels of the 
patient group and the control group (1.86 ± 1.17 and 
1.43 ± 0.79, respectively, p < 0.001). The ratio of 
cholesterol/HDL-c of patients was 4.24 ± 0.91. It was 
significantly higher in the patient group than in control 
(3.92 ± 1.50) (p < 0.05). However, the means of other 
components (cholesterol, HDL-c and LDL-c) were not 
significantly different between the two groups. 
 
Assessment of statins in psoriasis 
treatment 
Lipid profile 
In subgroup 1, the mean baseline of 
cholesterolemia was 5.45 ± 1.21 mm/L, which 
diminished to 4.20 ± 0.82 and 4.18 ± 0.72 mm/L (p < 
0.001) at the 4
th
 week and 8
th
 week, respectively. 
There was no difference between the triglyceride 
concentration at pretreatment and after 4 weeks of 
treatment, which was 2.07 ± 2.00 and 1.32 ± 0.84 
mm/L (p = 0.07), respectively; however, after 8 weeks, 
the triglyceride concentration was 1.26 ± 0.65 mm/L (p 
< 0.005). While the mean baseline LDL-c level was 
3.18 ± 0.7 mm/L, there was a significant difference in 
the 4
th
 week (2.31 ± 0.80 mm/L, p < 0.001) and 8
th
 
week of treatment (2.26 ± 0.7 mm/L, p < 0.001). 
However, the increasing HDL levels were negligible 
after 8 weeks of treatment (1.33 ± 0.31, 1.29 ± 0.24 
and 1.35 ± 0.24 at pretreatment, 4
th
 week and 8
th
 
week, respectively). Meanwhile, in subgroup 2, 
without treatment, there were no changes in lipid 
levels over time. 
 
Figure 2: Changes in the lipid profile after 8 weeks of treatment with 
simvastatin 
 
PASI score 
In subgroup 1, in which the treatment was 
combination of topical therapy and simvastatin, the 
mean baseline PASI score was 12.8 ± 5.87, which 
considerably declined to 8.58 ± 5.62 after 4 weeks of 
treatment (p < 0.01) and ultimately to 4.17 ± 3.81 at 
the 8
th
 week (p < 0.001) as shown in Table 3. 
Subgroup 2, treated only with topical therapy, did not 
have a significant difference in the mean PASI score 
between pretreatment and the 4
th
 week (11.8 ± 5.13 
vs 9.34 ± 5.01, p = 0.21); nevertheless, there was a 
considerable decrease to 6.52 ± 4.89 after 8 weeks of 
treatment (p < 0.001) as shown in Table 3. 
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Table 3. Change from baseline PASI score every 4 weeks 
according to treatment 
Time Baseline 4
th
 week 8
th
 week 
Group 1  12.8 ± 5.87 
8.58 ± 5.62 
P < 0.01 
4.17 ± 3.81 
P < 0.001 
Group 2 11.86 ± 5.13 
9.34 ± 5.01 
P = 0.21 
6.52 ± 4.89 
P < 0.001 
 
The PASI score reduction was more 
significant in subgroup 1 than in subgroup 2 (Mann-
Whitney test; p < 0.0001). After 4 weeks of treatment, 
the rates of patients who achieved PASI75 were 10% 
and 3.3% in subgroup 1 and subgroup 2, respectively. 
Patients who achieved PASI75 in subgroup 1 showed 
a significant increase compared with subgroup 2 after 
8 weeks (70% versus 40%, p < 0.05). 
 
Figure 3: The rates of patient achievement of PASI75 
 
 
 
Discussion 
 
Studies on lipid metabolism in psoriasis 
patients, focusing on skin surface lipids, epidermal 
phospholipids, serum lipids, LDL-c of the dermis layer, 
oxidative stress, and the correlation between the 
inflammatory index of clinical lesions and lipid profiles, 
have been conducted since the 20th century10. 
Several studies confirmed that there was dyslipidemia 
and psoriasis coexist [10], [11]. 
Our study included 128 patients and 128 
controls. There were no differences in age, gender, or 
BMI between the two study groups (Table 1). Our 
study used the Adult Treatment Panel III (ATP-III) 
guidelines from the National Cholesterol Education 
Program (NCEP) for the management of 
hypercholesterolemia, which was issued in 2001 and 
modified in 2004 as follows: cholesterol TP ≥ 6.20 
mm/L, triglyceride ≥ 2.26 mm/L, LDL-C ≥ 4.13 mm/L, 
and HDL-C < 1.03 mm/L. We found that the frequency 
of dyslipidemia in psoriasis patients was 53.9% for 
hypercholesterolemia, 25% for hypertriglyceridemia, 
21.9% for hypo-HDL-c, 20.3% for cholesterol/HDL-c > 
5, and 14.8% for hyper-LDL-c. 
The frequency of dyslipidemia in psoriasis 
patients varies among studies, ranging from 6.4 to 
50.9% [12]. In a study on psoriasis, Salihbegovic EM 
postulated that the frequency of dyslipidemia was 
62.8% (the frequencies of hypertriglyceridemia and 
hypo-HDL-c were 39% and 36%, respectively) [13]. A 
cross-sectional study of 120 Pakistani psoriasis 
patients found that the incidence of dyslipidemia was 
55.8% [14], which was similar to the incidence found 
in our study (53.9%). However, the comparison of 
dyslipidemia frequency among patients with psoriasis 
was only relative because the standard definition of 
dyslipidemia was different among authors. Our study 
compared the rate of dyslipidemia between the two 
groups. The results showed that the rates of 
hypercholesterolemia, hypertriglyceridemia, hypo-
HDL-c, and cholesterol/HDL-c > 5 in the psoriatic 
group increased significantly compared with those in 
the control group (p < 0.05). 
There have been many studies with a variety 
of lipid levels in psoriatic patients. The studies by 
Sahu S, Taheri Sarvtin, El Asmi MA postulated a 
statistically significant difference in the concentration 
of lipids between patients with psoriasis and controls 
[15], [16], [17]. In our study, the triglyceride level of the 
patient group was 1.86 ± 1.17 mm/L, and that of the 
control group was 1.43 ± 0.79 mm/L (p < 0.001). The 
ratio of cholesterol/HDL-c of patients was 4.24 ± 0.91, 
which was higher than that of the control group (p < 
0.05). Nevertheless, while comparing other elements 
of the lipid profile, we found no significant differences. 
Our study also found that in patients receiving 
oral simvastatin plus calcipotriol/betamethasone 
dipropionate steroid ointment, there was a critical 
decrease in the levels of cholesterol, triglyceride, and 
LDL-C, while the level of HDL-C remained stable. This 
finding suggested that simvastatin had a beneficial 
effect on the modulation of dyslipidemia, as 
mentioned above. Interestingly, we also found that 
simvastatin improved the PASI score in psoriatic 
patients. 
Treatment of plaque psoriasis after 8 weeks 
with calcipotriol/betamethasone dipropionate steroid 
ointment showed that there was a significant 
improvement in the PASI score. We also found a 
faster and more effective decrease in PASI score in 
patients with additional oral simvastatin than in 
patients without simvastatin. According to our study, 
after 4 weeks of treatment, in the subgroup that was 
treated with simvastatin, the efficacy of adding oral 
simvastatin was clear. The PASI score of subgroup 1 
at the baseline was 12.8 ± 5.87, which significantly 
diminished after 4 weeks of treatment (8.58 ± 5.62) (p 
< 0.01). Meanwhile, in the subgroup that did not 
include simvastatin, the PASI score decreased 
between pretreatment and the 4th week from 11.86 ± 
5.13 to 9.34 ± 5.01, respectively, which were not 
significantly different. This demonstrated that adding 
simvastatin (40 mg/d) to calcipotriol/betamethasone 
dipropionate ointment produced a significantly 
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beneficial effect in psoriatic treatment. 
The anti-inflammatory and immune-
modulatory effects of statins were identified as a 
potential experimental treatment for psoriasis in the 
1990s. Meanwhile, some studies did not find any 
effect of statins on psoriasis [18], while others 
suggested that statins might be useful in the treatment 
of psoriasis and other dermatologic disorders [9]. We 
hypothesised that the inhibition of leukocyte function-
associated-1 (LFA-1)-mediated adhesion of 
leukocytes to intercellular adhesion molecule-1 
(ICAM-1) or the inhibition of pro-inflammatory 
mediators produced clinical effects [19], [20]. 
A variety of mechanisms of cholesterol level 
modulation produced beneficial effects on psoriasis 
lesions, including (1) the downregulation of LFA-1, (2) 
the inhibition of leukocyte-endothelial adhesion, (3) 
extravasation and natural killer cell activity, (4) the 
inhibition of pro-inflammatory cytokines such as 
tumour necrosis factor-alpha and interleukin-1 and -6, 
(5) lowering the level of C-reactive protein, (6) the 
promotion of Th1 to Th2 cells and (7) the inhibition of 
Th1 cytokine receptors on T cells. As mentioned 
above, the activation of lymphocytes was limited and 
consequently impaired infiltration into the cutaneous 
lesion [21]. This result improved plaque psoriasis, 
which was confirmed by a lower PASI score.  
Few studies have reported that statins have 
been used specifically for the treatment of psoriasis. 
In 2007, Shirinsky et al. reported the efficacy of 
simvastatin in treating plaque psoriasis. Seven 
patients were prescribed simvastatin 40 mg/d and 
were assessed by the PASI and dermatology quality 
of life index (DLQI) at the 4th week and 8th week of 
treatment. After 8 weeks of treatment, they found a 
statistically significant improvement in the PASI score 
(47.34%) and DLQI score. Two patients achieved a 50 
per cent PASI response, and two patients achieved a 
75 per cent PASI response. Although there were 
many limitations of this study (small sample size, no 
control group), their results suggest that statins could 
have clinical benefits in plaque psoriasis treatment 
[22]. A double-blind study by Naseri M et al. recruited 
30 patients with plaque psoriasis and divided them, 
two groups. One received oral simvastatin (40 
mg/day) combined with a topical steroid (50% 
betamethasone in petrolatum) for 8 weeks, whereas 
the other group received oral placebo plus the same 
topical steroid. This study showed that the PASI score 
decreased significantly in both groups; however, the 
reduction in the PASI score was greater in patients 
who received simvastatin [23], which agrees with our 
results. Also, a study reported by Wolkenstein et al. 
disclosed that there was a decreased risk of psoriasis 
associated with the use of oral statins [24], [25], [26], 
[27].  
In conclusion, the limitations of our study 
included small sample size, a lack of blinding to 
treatment, and a lack of assessment of recurrence. 
Nevertheless, our study found that oral simvastatin 
could enhance the effect of topical therapy in psoriatic 
treatment. Considering the safety and benefits of 
statins, we suggest that statins are worth researching 
for their dual effects in psoriatic treatment, including 
decreasing the atherosclerotic disease burden 
through their lipid-lowering effects and decreasing 
psoriatic disease activity through their anti-
inflammatory, immunomodulatory properties. 
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